Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis

被引:44
作者
Al Masri, A
Gendler, SJ
机构
[1] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA
[2] Mayo Clin, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA
关键词
mucin; oncogene; transgenic mice; breast cancer; mammary gland;
D O I
10.1038/sj.onc.1208738
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
MUC1 is an integral membrane mucin glycoprotein that is normally expressed on the apical surface of most simple, secretory epithelia and hematopoietic cells. Overexpression of aberrantly glycosylated MUC1 is a hallmark of many carcinomas including 90% of breast carcinomas. MUC1 has been shown to bind to c-Src tyrosine kinase in vitro, whereby c-Src phosphorylates the MUC1 cytoplasmic domain at a YEKV motif. c-Src is an extensively studied nonreceptor tyrosine kinase implicated in mammary tumorigenesis. Previously, mouse mammary tumor virus-driven polyoma middle T-antigen (MMTV-PyV MT) transgenic mice crossed onto a Muc1 null background exhibited a significant delay in tumor progression. c-Src has been shown to interact with PyV MT, and to play an integral and indispensable role in MMTV-PyV MT-induced mammary tumorigenesis. Here, we determine the effect of Muc1 expression on c-Src activation and signaling. Examination of MMTV-PyV MT glands on a wild-type or Muc1 null background demonstrates that Muc1 expression promotes c-Src signaling by influencing its association with known substrates such as the p85 subunit of phosphatidylinositol 3-kinase and beta-catenin. These findings may provide a mechanism for the delay in tumor progression that is observed in the absence of Muc1.
引用
收藏
页码:5799 / 5808
页数:10
相关论文
共 56 条
[1]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[2]   STAT proteins:: From normal control of cellular events to tumorigenesis [J].
Calò, V ;
Migliavacca, M ;
Bazan, V ;
Macaluso, M ;
Buscemi, M ;
Gebbia, N ;
Russo, A .
JOURNAL OF CELLULAR PHYSIOLOGY, 2003, 197 (02) :157-168
[3]   The phosphoinositide 3-kinase pathway [J].
Cantley, LC .
SCIENCE, 2002, 296 (5573) :1655-1657
[4]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[5]  
Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010
[6]   AN 81-KD PROTEIN COMPLEXED WITH MIDDLE T-ANTIGEN AND PP60C-SRC - A POSSIBLE PHOSPHATIDYLINOSITOL KINASE [J].
COURTNEIDGE, SA ;
HEBER, A .
CELL, 1987, 50 (07) :1031-1037
[7]  
Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6
[8]   The SH3 domain directs acto-myosin-dependent targeting of v-Src to focal adhesions via phosphatidylinositol 3-kinase [J].
Fincham, VJ ;
Brunton, VG ;
Frame, MC .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (17) :6518-6536
[9]   Tumor-necrosis factor-alpha modulates mitogen-activated protein kinase activity of epidermal-growth-factor-stimulated MCF-7 breast cancer cells [J].
Flury, N ;
Eppenberger, U ;
Mueller, H .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 249 (02) :421-426
[10]  
FREUND R, 1992, AM J PATHOL, V141, P1409